4-(1,1-Dioxo-1,4-dihydro-1lambda6-benzo[1,4]thiazin-3-yl)-5-hydroxy-2H-pyridazin-3-ones as potent inhibitors of HCV NS5B polymerase
Ellis, D.A., Blazel, J.K., Webber, S.E., Tran, C.V., Dragovich, P.S., Sun, Z., Ruebsam, F., McGuire, H.M., Xiang, A.X., Zhao, J., Li, L.S., Zhou, Y., Han, Q., Kissinger, C.R., Showalter, R.E., Lardy, M., Shah, A.M., Tsan, M., Patel, R., LeBrun, L.A., Kamran, R., Bartkowski, D.M., Nolan, T.G., Norris, D.A., Sergeeva, M.V., Kirkovsky, L.(2008) Bioorg Med Chem Lett 18: 4628-4632
- PubMed: 18662878 
- DOI: https://doi.org/10.1016/j.bmcl.2008.07.014
- Primary Citation of Related Structures:  
3CWJ - PubMed Abstract: 
4-(1,1-Dioxo-1,4-dihydro-1lambda(6)-benzo[1,4]thiazin-3-yl)-5-hydroxy-2H-pyridazin-3-one analogs were discovered as a novel class of inhibitors of HCV NS5B polymerase. Structure-based design led to the identification of compound 3a that displayed potent inhibitory activities in biochemical and replicon assays (1b IC(50)<10 nM; 1b EC(50)=1.1 nM) as well as good stability toward human liver microsomes (HLM t(1/2)>60 min).
Organizational Affiliation: 
Anadys Pharmaceuticals, Inc., 3115 Merryfield Row, San Diego, CA 92121, USA.